Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Gatmaitan

Surgery Pensacola, FL Medical Doctor

NPI 1699897538 CMS profile 258314

1890 Summit Blvd Ste 120, Pensacola, FL 32503

Open in the dashboard

General payments

$266,618

322 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Gatmaitan of Pensacola, FL is reported in the CMS Open Payments database as having received $266,618 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,784 38
2024 General $38,627 69
2023 General $13,208 28
2022 General $39,058 38
2021 General $13,964 29
2020 General $72,960 63
2019 General $44,017 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Gatmaitan
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Patrick Gatmaitan were reported at $44,784. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Patrick Gatmaitan Surgery median Middle half National median
2019 $44,017 $253 $82–$1,521 $163
2020 $72,960 $131 $40–$706 $114
2021 $13,964 $168 $50–$904 $132
2022 $39,058 $224 $76–$1,218 $149
2023 $13,208 $253 $82–$1,255 $160
2024 $38,627 $279 $90–$1,381 $164
2025 $44,784 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $251,468 209 payments
  2. Intuitive Surgical, Inc. $10,823 35 payments
  3. Medtronic, Inc. $1,634 17 payments
  4. Boston Scientific Corporation $1,119 8 payments
  5. Transenterix, Inc. $549 3 payments
  6. Ethicon US, LLC $217 5 payments
  7. Baxter Healthcare $126 7 payments
  8. AbbVie, Inc. $122 6 payments
  9. Currax Pharmaceuticals LLC $114 8 payments
  10. Covidien LP $81 1 payment
  11. Other $363 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $227,570 55 payments
  2. Travel and Lodging $24,032 87 payments
  3. Food and Beverage $8,208 169 payments
  4. Education $6,790 8 payments
  5. Consulting Fee $10 2 payments
  6. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. Saxenda $164,378 123 payments
  2. Wegovy $86,581 75 payments
  3. DAVINCI XI $6,250 4 payments
  4. Da Vinci Surgical System $4,573 31 payments
  5. SpyGlass $1,119 8 payments
  6. Signia $784 10 payments
  7. LigaSure $693 2 payments
  8. Senhance Manipulator Arm $549 3 payments
  9. Senhance Cockpit $549 3 payments
  10. Senhance Node $549 3 payments
  11. Other $1,166 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

122

Median for General Surgery: 59

Drug cost

$2,106

Median for General Surgery: $393

Branded share of claims

18%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucralfate Generic 41 $1,209
Omeprazole Generic 37 $722
Ondansetron Odt Ondansetron Brand 22 $103
Hydromorphone Hcl Generic 22 $72

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$36,425

Medicare's payments for the services billed

Medicare patients

102

Average age 69

Services billed

219

74 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Depression 45%
Ischemic heart disease 32%
Diabetes 30%
Chronic kidney disease 30%
COPD 25%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $26,387
$26,387 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record